Quantitative Imaging: Turning Biological Signals Into Better Drug Development Decisions

Every drug development program is built on evidence-based decisions. Quantitative imaging helps strengthen those decisions by providing measurable biological data that reduces uncertainty from discovery through clinical development.

Bringing a new therapy from discovery to the clinic requires hundreds of scientific decisions, each with consequences for timelines, development costs, and patient outcomes. Researchers must determine whether a target is biologically relevant, whether a therapeutic reaches the relevant tissue, produces the expected biological effect and whether the resulting evidence is strong enough to justify advancing the program.

Quantitative imaging helps answer these questions by providing objective, non-invasive measurements of biological processes in living subjects. Technologies such as PET, SPECT, MRI, CT, and optical imaging do more than create visual readouts; they generate measurable data on biomarker expression, target accessibility, drug delivery and treatment response that can reduce uncertainty and improve confidence throughout the development lifecycle.

This distinction matters because quantitative imaging is not simply a way to observe biology; it is a way to measure whether a program is behaving as expected, where uncertainty remains, and what evidence is needed before the next investment decision.

When incorporated into an overall research strategy, imaging becomes much more than a supporting experiment—it becomes a tool for better decision-making.

Reducing uncertainty at every stage

One of the greatest challenges in drug development is making decisions with incomplete information. Traditional laboratory assays often provide valuable endpoint data but only capture a single moment in time. Imaging offers a different perspective by allowing researchers to evaluate biological processes longitudinally, following the same subject throughout a study and observing how therapies behave over time.

Early in development, imaging can confirm target expression, characterize disease models, and assess whether a therapeutic reaches the relevant tissue. As programs mature, imaging can support lead candidate comparison, quantify biodistribution, aid in dose related decisions, estimate dosimetry, and evaluate treatment response. In clinical studies, it continues to support patient stratification, biomarker validation, and treatment monitoring.

Although scientific questions evolve throughout development, the goal remains the same: to generate the evidence needed to make informed decisions before advancing a program. These decisions can include whether a model is appropriate, a candidate demonstrates sufficient tissue exposure, an observed response is biologically meaningful, or whether additional optimization is needed before moving to the next stage.

Imaging creates value beyond a single study

Quantitative imaging creates the greatest value when it is planned as part of an integrated development strategy with imaging endpoints matching scientific questions, decision points and development stages. By selecting imaging biomarkers that remain relevant across multiple stages, sponsors can generate consistent datasets that strengthen translational confidence and create continuity between preclinical and clinical research.

Combining complementary imaging modalities can further enhance this understanding. For example, PET or SPECT can quantify target engagement, while MRI can characterize anatomy, physiology, and tissue response. Together, these complementary datasets provide a more complete understanding of therapeutic performance than either modality alone.

This multimodal approach helps researchers answer complex biological questions while reducing the risk of advancing candidates with limited clinical potential.

Building an imaging strategy that supports better decisions

Every therapeutic program is different, which means there is no single imaging strategy that fits every study. The most effective approaches begin by identifying the scientific questions that need to be answered and then selecting the imaging technologies that provide the most meaningful evidence.
For sponsors, the practical question is not whether imaging can generate data, but which imaging strategy will generate the right evidence at the right development milestone.

At Perceptive Discovery, our Preclinical Imaging Services help sponsors design and execute multimodal imaging strategies across discovery, lead optimization, candidate selection, and IND-enabling studies. Whether the objective is target validation, biodistribution assessment, dosimetry, or biomarker evaluation, our team works alongside researchers to generate quantitative evidence that supports critical development decisions and helps move programs forward with greater confidence.

Learn how Perceptive Discovery’s Preclinical Imaging Services can help generate quantitative evidence for your next program: